Versor Investments LP Invests $499,000 in Orthofix Medical Inc. (NASDAQ:OFIX)

Versor Investments LP acquired a new position in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 28,600 shares of the medical device company's stock, valued at approximately $499,000. Versor Investments LP owned 0.07% of Orthofix Medical as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Franklin Resources Inc. raised its position in Orthofix Medical by 37.4% in the third quarter. Franklin Resources Inc. now owns 20,960 shares of the medical device company's stock worth $337,000 after acquiring an additional 5,702 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Orthofix Medical by 14.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 324,807 shares of the medical device company's stock worth $5,073,000 after purchasing an additional 39,901 shares in the last quarter. Barclays PLC raised its holdings in Orthofix Medical by 38.8% in the 3rd quarter. Barclays PLC now owns 122,472 shares of the medical device company's stock worth $1,912,000 after purchasing an additional 34,210 shares during the period. HighTower Advisors LLC lifted its position in Orthofix Medical by 114.9% during the third quarter. HighTower Advisors LLC now owns 89,183 shares of the medical device company's stock valued at $1,393,000 after purchasing an additional 47,680 shares in the last quarter. Finally, Kirr Marbach & Co. LLC IN bought a new stake in Orthofix Medical during the fourth quarter valued at about $532,000. Hedge funds and other institutional investors own 89.76% of the company's stock.

Remove Ads

Orthofix Medical Trading Up 1.7 %

NASDAQ:OFIX traded up $0.29 during midday trading on Wednesday, hitting $17.30. 268,925 shares of the company traded hands, compared to its average volume of 193,453. The firm has a market capitalization of $661.10 million, a P/E ratio of -5.53 and a beta of 1.10. The firm's fifty day moving average is $17.92 and its 200-day moving average is $17.39. Orthofix Medical Inc. has a 12-month low of $12.08 and a 12-month high of $20.73. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Orthofix Medical in a research note on Wednesday, February 26th. Stifel Nicolaus upgraded shares of Orthofix Medical from a "hold" rating to a "buy" rating and boosted their price target for the stock from $18.00 to $24.00 in a research report on Friday, November 8th. StockNews.com raised shares of Orthofix Medical from a "hold" rating to a "buy" rating in a research note on Tuesday, February 25th. Finally, Roth Mkm reissued a "buy" rating and issued a $22.00 price objective on shares of Orthofix Medical in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $23.33.

Insider Activity at Orthofix Medical

In other Orthofix Medical news, CEO Massimo Calafiore sold 10,078 shares of the company's stock in a transaction on Friday, January 10th. The stock was sold at an average price of $16.83, for a total value of $169,612.74. Following the transaction, the chief executive officer now owns 133,354 shares of the company's stock, valued at $2,244,347.82. This represents a 7.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Julie Andrews sold 4,655 shares of Orthofix Medical stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $17.89, for a total value of $83,277.95. Following the sale, the chief financial officer now owns 28,312 shares of the company's stock, valued at approximately $506,501.68. This trade represents a 14.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 25,442 shares of company stock worth $436,883. Insiders own 2.60% of the company's stock.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.